Orally administered nanoparticles for gastrointestinal applications

References

• 1. Alatab S, Sepanlou SG, Ikuta K et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5(1), 17–30 (2020).
  MedlineGoogle Scholar
• 2. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin. Proc. 94(1), 155–165 (2019).
  Medline CASGoogle Scholar
• 3. Kang S, Kim W, Jeong S et al. Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: implication in anti-inflammatory actions of 5-aminosalicylic acid. Free Radic. Biol. and Med. 108, 715–724 (2017).
  Medline CASGoogle Scholar
• 4. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14(1), 45–57 (2015).
  Medline CASGoogle Scholar
• 5. Nathan DM, Genuth S, Lachin J et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977–986 (1993).
  Medline CASGoogle Scholar
• 6. Dihingia A, Ozah D, Ghosh S et al. Vitamin K1 inversely correlates with glycemia and insulin resistance in patients with type 2 diabetes (T2D) and positively regulates SIRT1/AMPK pathway of glucose metabolism in liver of T2D mice and hepatocytes cultured in high glucose. J. Nutr. Biochem. 52, 103–114 (2018).
  Medline CASGoogle Scholar
• 7. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet 389(10080), 1741–1755 (2017).
  MedlineGoogle Scholar
• 8. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12(12), 720–727 (2015).
  MedlineGoogle Scholar
• 9. Peng Q, Wu W. Development and validation of oral chemotherapy self-management scale. BMC Cancer 20(1), 890 (2020).
  MedlineGoogle Scholar
• 10. Liu W, Han Y, Xin X et al. Biomimetic and temporal-controlled nanocarriers with ileum transporter targeting for achieving oral administration of chemotherapeutic drugs. J. Nanobiotechnol. 20(1), 281 (2022).
  Medline CASGoogle Scholar
• 11. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1(8336), 1273–1273 (1983).
  Medline CASGoogle Scholar
• 12. Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J. Cell. Biochem. 114(3), 491–497 (2013).
  Medline CASGoogle Scholar
• 13. Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit. Rev. Microbiol. 44(3), 371–392 (2018).
  Medline CASGoogle Scholar
• 14. Xu JL, Gu XY, Biao S, Wang ZC, Kun W, Li SP. Isolation and characterization of a carbendazim-degrading Rhodococcus sp djl-6. Curr. Microbiol. 53(1), 72–76 (2006).
  Medline CASGoogle Scholar
• 15. Selmanoglu G, Barlas N, Songur S, Kockaya EA. Carbendazim-induced haematological, biochemical and histopathological changes to the liver and kidney of male rats. Hum. Exp. Toxicol. 20(12), 625–630 (2001).
  Medline CASGoogle Scholar
• 16. Commission Implementing Regulation (EU) 2021/348. Official Journal of the European Union. L 68/174 (2021). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32021R0348
  Google Scholar